Instil Bio Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

TIL$6.35-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

Three Months Ended · Nine Months Ended
	September 30,		September 30,
	2024	2023	2024	2023
Operating expenses:
In-process research and development	$10,000	$—	$10,000	$—
Research and development	562	8,492	10,739	37,621
General and administrative	10,707	11,941	33,837	36,681
Restructuring and impairment charges	2,362	46,283	7,146	71,847
Total operating expenses	23,631	66,716	61,722	146,149
Loss from operations	(23,631)	(66,716)	(61,722)	(146,149)
Interest income	1,654	2,313	5,635	6,671
Interest expense	(2,007)	(2,003)	(5,988)	(3,229)
Other rental income	1,493	—	1,493	—
Other expense, net	(530)	(1,026)	(1,658)	(455)
Net loss	(23,021)	(67,432)	(62,240)	(143,162)
Other comprehensive loss:
Foreign currency translation	(291)	231	(252)	(210)
Unrealized gain on available-for-sale securities, net	398	39	80	178
Net comprehensive loss	$(22,914)	$(67,162)	$(62,412)	$(143,194)
Net loss per share, basic and diluted	$(3.54)	$(10.37)	$(9.57)	$(22.01)
Weighted-average shares used in computing net loss per share, basic and diluted	6,506,681	6,503,913	6,504,842	6,503,913

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.